REFERENCES
- Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
- De Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034–8.
- da Silva FC, et al. The quality of life of patients with newly diagnosed MI prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer 1996; 32A: 72–7.
- Fossa. SD, et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 1997; 31: 3–8.
- Essink-Bot ML, de Koning HJ, Nijs HGT, Kirkels WJ, van der Maas PJ, Schroder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 1998; 90: 925–31.
- Fowler FJ, Barry MJ, Lu-Yao G, Wasson J, Roman A, Wenneberg J. Effect of radical prostatectomy for prostate cancer on patients quality of life: results from a Medicare survey. Urology 1995; 45: 1007–15.
- Helgason AR, Adolfsson J, Dickman P. Fredrikson M, Arver S, Steineck G. Waning sexual function-the most important disease-specific distress for patients with prostate cancer. Br J Cancer 1996; 73: 1417–21.
- Herr HVV, Komblith AB, Ofman U. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993; 71: 1143–50.
- Lilleby W, Fossa SD, Wwhre H, Olsen DR. Long-term morbidity and quality of life in patients with localised prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phy. 1999; 43: 735–43.
- Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129–35.
- Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109–12.
- Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective short study. J Clin Oncol 1998; 16: 275–83.
- Tannock IF, Osoba D, Stockier MR, Ernst S, Neville AJ, Moore MJ, et al. Chemotherapy with mitozantrone plus predisone or prednisone alone for symptomatic hor-mone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756–64.